Cargando…

The transcription factor STAT5 drives mutation and imatinib resistance in chronic myeloid leukemia via ROS production

Detalles Bibliográficos
Autores principales:	Grundschober, Eva, Warsch, Wolfgang, Sexl, Veronika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194255/ http://dx.doi.org/10.1186/1471-2210-11-S2-A22

Ejemplares similares

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Adding a new facet to STAT5 in CML: Multitasking for leukemic cells
por: Warsch, Wolfgang, et al.
Publicado: (2013)

Screening for serine/threonine kinases phosphorylating Stat5
por: Berger, Angelika, et al.
Publicado: (2011)

Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
por: Kollmann, Sebastian, et al.
Publicado: (2019)

Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias
por: Hölbl, Andrea, et al.
Publicado: (2008)

STAT1 Ser727 – key regulator for NK cell-mediated cytotoxicity and tumor surveillance
por: Putz, Eva M, et al.
Publicado: (2008)

Unexpected role of STAT1 serine727 for NK cell function
por: Putz, Eva M, et al.
Publicado: (2009)

Update of recent studies in chronic myeloid leukemia
por: Seiter, Karen
Publicado: (2009)

Acute generalized exanthematous pustulosis from imatinib
por: Fu, Lisa W, et al.
Publicado: (2014)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Successful kidney transplantation in a patient with pre‐existing chronic myeloid leukemia treated with imatinib
por: Thiem, Ursula, et al.
Publicado: (2020)

Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia
por: Mencalha, André L, et al.
Publicado: (2014)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

STAT5A and STAT5B—Twins with Different Personalities in Hematopoiesis and Leukemia
por: Maurer, Barbara, et al.
Publicado: (2019)

Control of ROS production and T-cell turnover by HTLV-p13
por: Silic-Benussi, Micol, et al.
Publicado: (2011)

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
por: Cang, Shundong, et al.
Publicado: (2008)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
por: Enriquez, Virginia, et al.
Publicado: (2007)

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
por: Berger, A, et al.
Publicado: (2014)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Second hit influences the interaction between tumor cells and the immune system in a murine model of Burkitt's lymphoma
por: Schuster, Christian, et al.
Publicado: (2008)

Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
por: Berger, Angelika, et al.
Publicado: (2014)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Phase II AIDS Malignancy Consortium (AMC) trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS)
por: Koon, Henry B, et al.
Publicado: (2010)

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia
por: Blouet, Anaïse, et al.
Publicado: (2018)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

OR10-001 - Altered mitochondrial ROS and metabolism in TRAPS
por: Siegel, R, et al.
Publicado: (2013)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
por: Tadesse, Fisihatsion, et al.
Publicado: (2021)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Regulation of host cellular gene transcription by Bovine Leukemia Virus (BLV) Tax, wild type and mutants
por: Arainga-Ramirez, Mariluz, et al.
Publicado: (2011)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m3am2t92mriffa7oapuful1kdj